

Sentara Health Plans| Post Claim Clinical Appropriateness (PCCA) Submission Tutorial

Radiation Therapy and Medical Oncology

Outline

83

- Post Claim Clinical Appropriateness (PCCA) Submission Steps
- PCCA Requirements
- Radiation Therapy PCCA Submission
- Medical Oncology PCCA Submission



PCCA Submission Steps





PCCA Requirements

	Rule
Program Start	Date of service must be on or after the program start
Member Eligibility	Must be eligible on date of service
PCCA Review Timeframe	Post Claim Clinical Appropriateness (PCCA) Review is limited to 3-365 calendar days after the date of service (for both MOC and RAD)
Claim No. Configuration	<i>Current Field Requirement: 11 characters</i> Claim # is only 10 digits – please add O (zero) at the end to satisfy character requirements
Lines of Business (LOB) Membership	Commercial, Medicare & Medicaid
Programs	Medical Oncology and Radiation Oncology



Prerequisites prior to initiating a PCCA

- Review patient records to identify if a case has already been submitted to avoid duplicates
- Review managed drug or CPT Code list to understand if an authorization is required.
- Locate the ten-digit claim number and date of claim submission
- Identify the required demographic and clinical data to ensure you have all the necessary information to submit a case via the ProviderPortal





Enter the Claim Number and Claim Submission Date

SMITH, JOHN Edit Member #: 107791102 Date of service: Date of service: Date of Birth: 9/19/1967 Health Plan: Ordering Provider:	Hide Details 10/1/2020 Optima Health	
Step 2: Please select the Ordering Provider from the list below. Ordering Provider Search Search Type: Order	Post Medical Necessity Review Has the Health Plan directed you to AIM to submit a Post Claim Case after the claim was processed?	
Name TIN or NPI Address	●Yes ONO Please provide the following information Claim Number Claim Submission Date	pecialty the Health Plan the Health Plan the Tiew dropdown to view all providers.
First Name:	OK	
Last Name:		
State Virginia		

All other intake steps after this point are the same as a prospective case (Select Ordering Provider, Servicing Provider and complete Clinical Intake) Initiate a request in the Provider Portal like any other request and indicate the appropriate Date of Service.

The system will identify the request as a PCCA case based on the Date of Service and will ask for the following information:

- PCCA claim numbers consist of 11 digit alphanumeric values
- If claim only has 10 digits add a '0' at the end
- Claim Submission Date

Continue with entering the standard clinical information and submit the request.



How to submit PCCA case for Medical Oncology

Note: Carelon Medical Benefits Management maintains the confidentiality of all protected health information. All data displayed is fictional and any resemblance to real persons is purely coincidental.



Provider Portal Home Page

DEMO TRAINING	anage Your Seference User Profile Seference Desk
Start Your Order Request Here	Service Date * MM/DD/YYYY
Check Order Status	Member Details: First Name * jane
View Order History	Last Name * 85doe Member ID * 376699999
Check Member's Eligibility	Date of Birth * 01/01/1959
Check Claim Status	 For all Radiology requests use Date of Service. For Genetic Testing use the testing date. For all other requests, use Service Date. Do not include suffix/dependent code. For Federal Employee (FEP) members, please include the leading "R" in the search. If the member is not found, remove the leading "R" and search again. If there is an asterisk as part of the Member ID, do not enter it
Access Your Optinet Registration	 Member not found? Try entering only the first 2 characters of the patient's first and last name.

To initiate a prior authorization request:

- 1. Enter the "Date of Service"
- 2. Provide the following member information:
 - Member First Name
 - Member Last Name
 - Member ID
 - Member DOB
- 3. Next, chose "Find this Member"

You can also:

- Check Order Status
- View Order History
- Manage Your Physician List
- Manage Your User Profile
- Reference Desk

83

Order Type Selection

Order Request			Medicare AUC Logout
Back to Homepage			Print Preview
Member Details			
23 MAIN STREET SUITE 500 BRIDGEWATER, NJ 08807-6102 Service Date: 2/27/2023	Date of Birth: 09/08/1973 Age: 49 Male	Member ID: Alpha Prefix	: Edit Service Date
			De Loit Service Date
Eligibility Details			
Effective: 05/17/2021-12/31/9999	Product Code: Employer Group ID:		
The following solutions for the service date entered To initiate a request, please select the solution and then click the	require a Pre-Authorization: Start Order Request to start your request.		
View Code List Nuclear Medicine, PET	View Code List	Chemotherapy and Supportive Drugs Review of cancer drugs, side effect management and treatment pathways	
Urgent requests are not expected given the scope of Carelo	n's services. If you have any questions about a possible urgent reques	st, please contact 866-766-0250.	Start Order Request
The following solutions for the service date entered the member's ID card if you have any questions reg	I do not require Pre-Authorization by Carelon. Please no arding coverage or Pre-Authorization requirements.	te that benefit limits, if applicable, will still be applied. Contac	t the health plan using the number on the back of
View Code List Joint Surgery, Spine Surgery & Interventional Pain Management			

Eligible solutions will display for the member and will be selectable

The medical oncology program is called Chemotherapy and Supportive Drugs.



Member History

Please verify the list of Or	Please verify the list of Order Requests below to ensure you are not entering a duplicate request.											
Member History												
Order ID	🟚 Pro	cedure Description	¢	ICD	¢	Disease	¢	Start Date	End Date	Ordering Provider 🟚	Outcome 😰	Summary
Voluntarily Withdrawn	Nive	olumab		C43.0		Malignant melanoma of lip		2/21/2022	8/29/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Ipili	mumab		C43.0		Malignant melanoma of lip		2/21/2022	8/29/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Dex	amethasone Sodium Phosphate		C43.0		Malignant melanoma of lip		2/21/2022	8/29/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	AK	YNZEO		C50.01	1	Mal neo nipple&areola,rt fem breast		1/19/2022	5/4/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Cis	platin		C00.0		Malig neoplasm external upper lip		1/13/2022	3/31/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Nive	olumab		C43.0		Malignant melanoma of lip		12/30/2021	7/7/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Ipili	mumab		C43.0		Malignant melanoma of lip		12/30/2021	7/7/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Dex	amethasone Sodium Phosphate		C43.0		Malignant melanoma of lip		12/30/2021	7/7/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Nive	olumab		C43.0		Malignant melanoma of lip		12/23/2021	6/30/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Voluntarily Withdrawn	Ipili	mumab		C43.0		Malignant melanoma of lip		12/23/2021	6/30/2022	SCULLY, THOMAS	Voluntary Cancellation	View
Ka aa 1 2 3 4	5 H H	l i i i i i i i i i i i i i i i i i i i								DISPLAYIN	G 1–10 OF 58 R	ESULTS

Historical order requests will display in the member history

Select "Next" to proceed with the order request entry or "Withdraw the request" if applicable



Confirm PCCA Review Type

Clear

Search

All other intake steps after this point are the same as a prospective case (Select Ordering Provider, Servicing Provider and complete Clinical Intake)

- System recognizes the user is initiating a PCCA case.
- User validates the PCCA request and enters claim number.
- PCCA claim numbers consist of 11 digit alpha-numeric values.
- If claim only has 10 digits add a '0' at the end
- User searches and selects Ordering Provider.

Select Ordering Provider

Crder Request									Logout
						Step: 1	34	560	78
85PARKER, MARY JANE Z Edit Member #: 3766387660 Date of sin Date of Birth: 1/1/1943 Health Pla Ordering Provider:	ervice: 8 an:	/30/2022	Hide Details						
tep 2: Please select the Ordering Provider from the	list below.								
Ordering Provider Search	Re	cent	Favorites	Search Results				View:	Local 🛩
Name	Ordering F Favorite to	Providers Name	¢	Address 👘	Caty et	Specially	de H	sath Plan	¢
TIN or NPI Address		SMITH JOS	HUA	700 PARK RIDGE LN	NORTH FOND DU LAC	Radiology			
	介	SCULLY TH	QMAS	226 S WOODS MILL RD STE 40W	CHESTERFIELD	Urology			
First Name:		SHARPE_BE	RYAN	18051 RIVER AVE STE 200	NOBLESVILLE	Family Practice			
Last Name		SCULLY TH	OMAS	2 PROGRESS POINT PKWY	O FALLON	Urology			
	公	SMITH JOS	EPH	1701 SENATE BLVD	INDIANAPOLIS	Pulmonary Diseases			
State Texas	☆	BUTTERMAN GLENN	NN.	730 10TH AVE	BALDWIN	Orthopedic Surgery			
	160 A.C. 🚺 1	5 . 601				DISPLAYING	1-6 OF	6 RES	ULTS
Search	Withdraw th	s request							

Select the ordering provider by clicking on the physician's name

Ordering providers that are associated with the requesting user's registration will be available for selection

Providers can be added to "Favorites" by clicking on the start to the left of the provider's name



Ordering Provider Fax Number

83

Order Request						Step 1	34	667	Logout
85PARKER, MARY JANE ✓ Edit Member # 3766387660 Date of Birth: 1/1/1943 Ordering Provider: Health P	ienvice 8 tan:	Hide Details							
Ordering Provider Scarch Search Type:	Re	Cont Favorites	Search Results	_				View: I	Local 👻
Name	Favorite 1		about the second from some from	a balan				lealth Plan	
TIN or NPI Address	*	FAX Number (987) 654-6543	physician's secure fax numbe	r below.	FOND	Radiology			
		Why do you need this?			RFIELD	Urology			
First Name	Ŷ	Tras onavaiaus			VILLE	Family Practice			
Last Name.		SCALLT THANKS	2 PROGRESS POINT PRWY	UTALLO	N	Urology			
	ŝ	SMITH JOSEPH	1701 SENATE BLVD	INDIANA	POUS	Pulmonary Diseases			
State Texas		BUTTERMANN. GLENN	730 10TH AVE	BALDWI	N	Orthopedic Surgery			
	ser er 🖬 s	i ant				DISPLAYING	1-6 O	F 6 RES	ULTS
Search	Withdraw the	s request							

Enter or confirm the fax number to be used when communicating with the ordering provider

Press the **"Save**" button to continue

Verify Dispensing Date

Order Request		
		Step: 123456
5PARKER, MARY JANE Edit ember #: 3766387660 Date of service: ate of Birth: 1/1/1943 Health Plan: rdering Provider: SMITH, JOSHUA Edit	Hide Details 8/30/2022	
0 3: Please enter the Dispensing Start Date if it prior to the T Dispensing Date 08/30/2022	eatment Start Date	
/ithdraw this request Next		

The "**Dispensing Date**" will default to the start date for the treatment; verify and modify as needed

Select the "**Next**" button to continue

Note: If the requested drugs will be procured from an outside pharmaceutical supplier, the user can enter a dispensing date prior to the treatment start date



Select Dispensing/Servicing Provider

Grder Request								Logout
						Step: 1	2345	678
85PARKER, MARY JANE Edit Member #: 3766387660 Date of Birth: 1/1/1943 Ordering Provider: SMITH, JOSHUA	8/30/2022 ice:	Hide Details						
Step 4: Please Choose a Dispensing Provider.	Provider Search Res	ults						
	Dispensing Provider	Address	City	State	Phone	Distance	Action	Мар
	<u>SMITH, JOSHUA</u>	700 PARK RIDGE LN	NORTH FOND DU LAC	WI	888-720-2012	892.44	View Details	View Map
	KK KK 1 DD DD				DIS	SPLAYING	1–1 OF 1	RESULTS
	Withdraw this request							

Select the **dispensing provider** by clicking on the name from the default list of frequently used providers that displays

You can search for the dispensing provider if they are not listed by selecting the "Find Dispensing Provider" button and completing a search



Dispensing Provider Place of Service Selection

Order Request								Logout
						Step: 1	2345	
85PARKER, MARY JANE Edit Member #: 3766387660 Date of Birth: 1/1/1943 Date of Birth: 1/1/1943 Ordering Provider: SMITH, JOSHUA	8/30/2022 ice: Anthem CR	Hide Details						
Step 4: Please Choose a Dispensing Provider.								
Find Dispensing Provider	Provider Search Res							
	Dispensing Provider	Address	City	State	Phone	Distance	Action	Мар
	SMITH, JOSHUA	700 PARK RIDGE LN	NORTH FOND DU LAC	WI	888-720-2012	892.44	View Details	<u>View Map</u>
	KK KK 1 DD DDI	SMITH, JOSHUA				PLAYING	6 1–1 OF 1	RESULTS
	Withdraw this request	Select Place of S Select OFFICE OUTPATIENT H AMBULATORY HOME	HOSPITAL INFUSION CENTER SURGICAL CENTER		~			

Select the place of service from the drop-down list

The place of service corresponds to the site where the chemotherapy will be administered



Request Services

Request Services

J9354 | Ado-Tra

|8999 | Afatinib

J9015 | Aldesleu J8999 | Alectinii

18999 | Alpelisit

18999 | Alpelisi

• Some drugs used in a cancer treatment regimen require prior authorization by Carelon; other drugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health plan. For those drugs within a regimen NOT preauthorized by Carelon, clinical information is requested to determine Pathway eligibility.

Search	
Drugs	Regimen
1	Name
Partial Match - J	
J8999 Abemaciclib (Verzenio) PO	Show 🗸
J8999 Abiraterone Acetate (Yonsa) PO	
J8999 Abiraterone Acetate (Zytiga) PO	
18999 Acalabr	CONTINUE

Request Services

• Some drugs used in a cancer treatment regimen require prior authorization by Carelon; other drugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health plan. For those drugs within a regimen NOT preauthorized by Carelon, clinical information is requested to determine Pathway eligibility.

Search

Drugs	Regimen	
HCPCS, Generic or Brand Name	fal	
	Partial Match - fol	
Register a Clinical Trial	bev FOLFOX	,
	Rev- FOL FOX6	

ALL drugs being prescribed as part of the care plan should be entered

Search for individual drugs by:

- HCPCs Code (J-Code)
- Generic name
- Brand name

Clicking on the drug name in the results list adds it to the "Selected Drugs" list

Click "**Continue**" to proceed once all drugs have been entered



Request Services | Clinical Trial

or the health plan. For those drugs within a regimen NOT pre	eauthorized by Carelon, clinical information is requested to determine Pathway el	igibility.	
Search			
Drugs	Regimen		
HCPCS, Generic or Brand Name	Name		
Register a Clinical Trial		She	w 🗸
CANCEL		CONT	INUE
EQUEST. Services	sings may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health pla	In. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regimen require prior authorization by Carelon: other d presubtrices by Carelon, clinical information is requested to determine Pathway eligibility. Parch Ings HCPCS, Generic or Brand Name	brugs may need review by other entities; such as pharmaceutical benefits management (PBM) companies or the health pla Regimen	N. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regimen require prior authorization by Carelon: other d preauthorized by Carelon. clinical information is requested to determine Pathway eligibility. exarch Micros. Generic or Brand Name tegister a Clinical Trial	Brugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health pla Regimen	an. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer breatment regimen require prior authoritation by Carelon: other d prograuthorized by Carelon, clinical information is requested to determine Pathway eligibility. Program RCPCs: Generic or Brand Name RCPCs	bugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health pla Regimen Name	an. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regimen require prior authorization by Carelon: other d presubtrices by Carelon, clinical information is requested to determine Pathway eligibility. Press HCPCs: Generic or Brand Name HCPCs: Gen	Prugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health plu Regimen Register a Clinical Trial	an. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regime nequire prior authoritation by Carelon: other of presultances by Carelon. chical information is requested to determine Pathway eligibility. Parach Progs Process Generic of Brand Name Pr	Prugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health pla Regimen Reme Register a Clinical Trial Face Page URL *	an. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regimen require prior authorization by Carelon: other d praseuthorized by Carelon, clinical information is requested to determine Pathway eligibility. Prase HCPCs: Generic or Brand Name HCPCs: G	Register a Clinical Trial Face Page URL *	an. For those drugs within a regimen NOT	
equest Services Some drugs used in a cancer treatment regimen require prior authorization by Carelon: other dispersion of the service of the	Register a Clinical Trial Face Page URL * I don't have the NCT Number	an. For those drugs within a regimen NOT	
Some drugs used in a cancer treatment regime nequire prior authorization by Carelon: other drugs presatherized by Carelon: clinical information is requested to determine Pathway eligibility. earch Drugs MCCDS: Generic of Band Name Register a Clinical Trial NCT Number I don't have the NCT Number	hugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies of the health plu Register a Clinical Trial Face Page URL * I don't have the NCT Number	an. For those drugs within a regimen NOT	

To Register a Clinical Trail:

- Click "Show" link to expand the field
- Enter NCT Number and click verify
 - Messaging will display if an NCT number is valid or invalid
- If NCT number is not known, select "I don't have the NCT Number" check box
 - User can enter the Face Page URL

Click "Continue" to proceed

Hide 🔨

Request Services | Biosimilars

Request Services

O Some drugs used in a cancer treatment regimen require prior authorization by Carelon; other drugs may need review by other entities, such as pharmaceutical benefits management (PBM) companies or the health plan. For those drugs within a regimen NOT preauthorized by Carelon, clinical information is requested to determine Pathway eligibility.

Search

Drugs	Regimen
HCPCS, Generic or Brand Name	
	You may only request one Regimen for each authorization; however, you may add additional Drugs to the selected Regimen. To search for another Regimen, please remove the selected Regimen.

Selected Regimen

bevacizumab, fluorouracil, leucovorin and oxaliplatin (bev FOLFOX)	× Delete
J9263 Oxaliplatin (Oxaliplatin) IV	
J9190 Fluorouracil (Fluorouracil) IV	
Select Drugs:	
Select	~
Select	
C9257 Bevacizumab (Avastin) IV	
J9035 Bevacizumab (Avastin) IV	
e Q5107 Bevacizumab-awwb (Mvasi) IV	
Q5118 Bevacizumab-bvzr (Zirabev) IV	× Delete

If a regimen contains drugs with biosimilars, the user will need to specify a biosimilar for each drug using the dropdown boxes

Confirm the selected HCPCS code is correct

Note: Only one Regimen can be requested at a time, however multiple drugs can be entered with or without a Regimen



Request Services | All drugs requested

Request Services

53

Search	
Drugs	Regimen
HCPCS, Generic or Brand Name	
	You may only request one Regimen for each authorization; however, you may add additional Drugs to the se Regimen. To search for another Regimen, please remove the selected Regimen.
elected Regimen	
Rituxan. Doxorubicin. Vincristine. Cyclophosphamide. Prednisone (R-CHOP)	× Delete
J9070 Cyclophosphamide (Cytoxan)	
J9000 Doxorubicin (Adriamycin)	
J/STO Predhisone (Pediapred) J9310 Rituxumab (Rituxan)	
J9999 Vincristine (Vincasar PFS)	
elected Drugs	
J2505 pegfilgrastim (Neulasta)	× Delete
CANCEL	CON
LITTI TALEN	

After all drugs have been added to the request, verify selections and click "**Continue**"

Clinical Scenario

Clinical Scenario

Tumor Type*		ICD-10 Code*				
Select		Search				
Pathology * You can find this section of the el	s information in the pathology ectronic record					
Select						
Stage *						
Select						
Select	Tumor Type*			ICD-10 Code *		
	Colon	-	Clear	C18.0 Malignant neoplasm of cecum	▼ Clear	
CANCEL B	Pathology * You can find this information in the pathology section	of the electronic record		ICD-10 Code dropdown choices are related to tumor type: Colon		
	Adenocarcinoma	•	Clear			
	Stage *					
			Clear			
	Stage IIB	•	Clear			
	Stage IIB Line of Treatment *	•	Clear			
	Stage IIB Line of Treatment * 1st Line CLEAR ALL	•	Clear			

User will complete clinical scenario information

- All fields on this page are required
- Answers can be selected via the drop-down boxes depending on the tumor type
- User has the option to "Clear" a selected answer next to each field or "Clear All"
 - Clearing a field will clear answers in the subsequent fields
- Selections on this screen will modify any subsequent biomarker or clinical justification questions asked later in the process

Once all fields have been completed, user can click "**Save & Exit**" or "**Continue**" to proceed

Biomarkers

Biomarkers

What are the biomarker (or other tests listed below) results?

BRAF BRAF Mutated BRAF Wild-Type BRAF Unknown

KRAS KRAS Mutated KRAS Wild-Type KRAS Unknown

NRAS NRAS Mutated NRAS Wild-Type NRAS Unknown

NTRK 1/2/3 gene fusion

○ NTRK 1/2/3 Positive ○ NTRK 1/2/3 Negative ○ NTRK 1/2/3 Unknown

CANCEL BACK

SAVE & EXIT CONTINUE

User will complete Biomarkers and other test results depending on the clinical scenario entered on the request.

 Select "Unknown" if biomarker value is unknown or not reported

Once all fields have been completed, user can click "Save & Exit" or "Continue" to proceed



Performance Status

Performance Status

What is the patient's performance status?

- ECOG Scale Karnofsky Scale
- 🔘 0 Fully active, able to carry on all pre-disease performance without restriction
- 🔘 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature
- 🔘 2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
- 3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
- 4 Completely disabled and cannot carry on any selfcare; totally confined to a bed or chair
- Unknown

CANCEL	BACK
Contraction of the second s	and the second

	
SAVE & EXIT	CONTINUE

User will enter performance status

- Select "Unknown" if performance status is unknown
- System defaults to "ECOG Scale"
- "Karnofsky Scale" is available if needed
- System will default to "Lansky Scale" for patients 18 and under

Once all fields have been completed, user can click "Save & Exit" or "Continue" to proceed



Additional Biomarkers – Off Pathway Regimen

Additional Biomarkers

Please enter additional biomarker (or other tests listed below) results for potential alternative regimens

Microsatellite Instability/mismatch repair

MSI/MMR Unknown OSI/MMR Microsatellite Instability High (Msi-H)/Deficient Mismatch Repair (Dmmr)
 MSI/MMR Microsatellite Stable Or Instability Low (Mss Or Msi-L)/Proficient Mismatch Repair (Pmmr)

CANCEL BACK

SAVE & EXIT CONTINUE

User will be prompted to enter additional biomarkers/other test results *if an Off-Pathway regimen is selected*

- Alternative regimens will display based on the additional biomarkers/other test results selected
- Select "Unknown" if Biomarker is unknown

Once all fields have been completed, user can click **"Save & Exit**" or **"Continue**" to proceed

83

Alternative Regimens

Alternative Regimens

Based on your clinical scenario, please consider choosing an alternative Regimen by selecting a row in the table below and clicking 'Update Regimen' to continue.

	Regimen Name	(Nickname)	Required I	Biomarker(s)	Pathway Eligible
	trastuzumab (t	rastuz)	5q- (5q mii	nus), HER2	No
	trastuzumab (t	rastuz)			
Alternative Reg	imens				
Selected Drugs					
You have requested drugs that Q5107 Bevacizumab-awwb (Mw. J9190 Fluorouracil (Fluorouracil) J0640 Leucovorin Calcium (Leuc J9263 Oxaliplatin (Oxaliplatin)	may require additional rev asi) IV) IV ovorin Calcium) IJ IV	iew:			SAVE & EXIT UPDATE REGIMEN
Based on your clinical scenario.	S , please consider choosing a	an alternative Regimen by selecting a row in the	table below and clicking 'U	odate Regimen' to continue.	
Regimen Name (Nickname)		Required Biomarker(s)		Pathway Eligible	
Keytruda (Keytruda)		BRAF, KRAS, MSI/MMR, NRAS, NTRK 1/2/3		Yes	
CANCEL BACK			SAVE & EXIT CON	TINUE WITH CURRENT DRUG SELECTION	

Based on patient's diagnosis and biomarker test results, the Alternative Regimens screen displays

- Eligible On-Pathway or Off-Pathway alternative regimens will be provided
- User can select an alternative • regimen and click "Update Regimen"

OR

User can continue with the • current drugs and click "Continue with Current Drug Selection"



Dosing Schedule

eight *	es as final doses Unit *		Weight*	un Un	it *				CREATE NEW DOSING SCH
50	inches	-	120	p	ounds 👻				
Bev- FOLFOX6 - Pathway Ineligib	le								
Drugs		Dose Amount		Final Dose	Route	Daily Frequency	Schedule	Cycle Length	Cycles
Bevacizumab (Avastin) Oxaliplatin (Oxaliplatin) Fluorouracil (Fluorouracil)		5.000 MG/KG 85.000 MG/M2 400.000 MG/M2		272.000 MG 129.200 MG 608.000 MG	IV	QD	D1 D1 D1	14 Days	Cycle 1
Leucovorin Calcium (Leucovorin C	Calcium)	1,200.000 MG/M2 400.000 MG/M2		1,824.000 MG 608.000 MG			D1, 2 D1		
Huorouracii (Huorouracii) Leucovorin Calcium (Leucovorin C	Calcium)	1,200.000 MG/M2 400.000 MG/M2		1,824.000 MG 608.000 MG			D1,2 D1		SEL
Ruorouracii (Ruorouracii) Leucovorin Calcium (Leucovorin C QA DS bev FOLFOX - Pathway Inc	Calcium)	1,200.000 MG/M2 400.000 MG/M2		1,824.000 MG 608.000 MG			D1,2 D1		SEL
Puorouracii (PiudroUracii) Leucovorin Calcium (Leucovorin C QA DS bev FOLFOX - Pathway Inc Drugs	Calcium)	1,200.000 MG/M2 400.000 MG/M2		1,824.000 MG 608.000 MG Final Dose	Route	Daily Frequency	D1,2 D1 Schedule	Cycle Length	SEL Cycles
QA DS bev FOLFOX - Pathway Inc Drugs Bevacizumab (Avastin) Oxaliplatin (Oxaliplatin) Fluorouracii (Fluorouracii) Leucovorin Calcium (Leucovorin C	Calcium)	1,200.000 MG/M2 400.000 MG/M2 Dose Amount 5.000 MG/KG 85.000 MG/M2 400.000 MG/M2		1,824.000 MG 608.000 MG Final Dose 272.000 MG 129.200 MG 608.000 MG 608.000 MG	Route	Daily Frequency	D1,2 D1 Schedule D1 D1 D1 D1 D1 D1	Cycle Length	SEL Cycles Cycle 1

Multiple dosing schedules could display, and user can Select, Edit or Create a Dosing Schedule

User is required to enter Height and Weight

- Some drugs have weightbased doses
- System will calculate the flat dose
- Final Dose column will display once height and weight are entered



Dosing Schedule | Create a New Dosing Schedule

Dosing Schedule - Edit

Inter height and weight to see doses as final doses

Height	Unit	Weight	Unit
60	inches	130	pounds

New Dosing Schedule - Pathway Ineligible

Drugs	Dose	On Cycle		
Trastuzumab (Herceptin)	No Doses exist for Drug/Cycle Length combination	Select	/ Edit	X Delete
Carboplatin (Paraplatin)	No Doses exist for Drug/Cycle Length combination	Select	Edit	X Delete
Pertuzumab (Perjeta)	No Doses exist for Drug/Cycle Length combination	Select	/ Edit	X Delete
Docetaxel (DOCEtaxel)	No Doses exist for Drug/Cycle Length combination	Select	ø Edit	x Delete
Add Drug Dose				

User can create a new drug dose if one does not match for the intended drug or regimen

Cycle length, number of cycles, dose, etc. will need to be entered

Select "**Confirm Changes**" once dosing has been entered

Dosing Schedule | Custom Treatment

Dosing Schedule

Enter height and	l weight to se	ee doses as	final doses
------------------	----------------	-------------	-------------

Height	Unit		We	
	inches	-		

eight	Unit
	pounds

The combination of drugs that have been requested do not have an associated dosing schedule. Please create a dosing schedule for the patient

New Dosing Schedule - Pathway Ineligible

Cycle Length Day(s) *	Number of Cycles *		
Drugs	Dose	On Cycle	
Select	No Doses exist for Drug/Cycle Length combination	Select	<pre></pre>
Add Drug Dose			
f the drug dose you are looking for doesn't exist, you can c	create a new dose by <u>clicking here</u>		
			+ Add a new Cy
			CONFIRM CHANGE
		L	

When a custom treatment is entered on a request:

- System will not identify any specific dosing related to the custom regimen entered
- User will need to enter a new dosing schedule and complete each field
- Custom regimens will display as "Pathway Ineligible"

Select "**Confirm Changes**" once dosing has been entered

Note: Custom treatments may pend for additional clinical review



Regimen | Pathway eligibility

Drugs	Dose Amount	Final Dose	Route	Daily Frequency	Schedule	Cycle Length	Cycles
Carboplatin Paraplatin) Docetaxel (DOCEtaxel) Trastuzumab Herceptin) Trastuzumab Herceptin) Pertuzumab (Perjeta) Pertuzumab (Perjeta)	6.000 AUC 75.000 MG/M2 8.000 MG/KG 6.000 MG/KG 420.000 MG 840.000 MG	900.000 MG 118.500 MG 472.000 MG 354.000 MG 420.000 MG 840.000 MG	IV	QD	D1 D1 D1 D1 D1 D1 D1	21 Days	Cycles 1-6
							CEL DOT
							SELECT
CHP O21 C1-6 + HP Ma athway Ineligible	intenance C6						SELECT
CHP_O21 C1-6 + HP Ma athway Ineligible Drugs	intenance C6 Dose Amount	Final Dose	Route	Daily Frequency	Schedule	Cycle Length	SELECT

Pathway eligibility displays next to the regimen name

If dosing schedule is correct, click "Select" to continue



Additional Clinical Information



Additional clinical questions may display when requesting supportive drugs

 User should "Confirm" the questions that display and select the appropriate responses

Once all fields have been completed, user can click "Save & Exit" or "Continue" to proceed



Additional Clinical Information

Additional Clinical Information

Does the individual have adequate cardiac function? *	
○ Yes	
○ No	
OUnknown	
Will cardiac function be monitored at regular intervals (e.g. every 3 months) during treatment? st	
○ Yes	
○ No	
OUnknown	
Has the disease progressed on or after prior treatment that contained pertuzumab (Perjeta)? st	
○ Yes	
○ No	
OUnknown	
CANCEL BACK	SAVE & EXIT CONTINUE

Additional clinical questions may display based on the clinical scenario entered on the request

• User should answer the questions accordingly

Once all questions have been completed, user can click "Save & Exit" or "Continue" to proceed



Review and Continue

Intermediation of provide 1 (Stangard Diversity 1) (Stangard	
Review & Continue Your request for J9045 Carboplatin (Paraplatin), J9171 Docetaxel (DOCEtaxel), J9306 Pertuzumab (Perjeta), J9355 Trastuzumab (Herceptin) does not require additional review at this time Your request for J9045 Carboplatin (Paraplatin), J9171 Docetaxel (DOCEtaxel), J9306 Pertuzumab (Perjeta), J9355 Trastuzumab (Herceptin) does not require additional review at this time Your request for J9045 Carboplatin (Paraplatin), J9171 Docetaxel (DOCEtaxel), J9306 Pertuzumab (Perjeta), J9355 Trastuzumab (Herceptin) does not require additional review at this time Your request for J2506 Pergfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at this time Your request for J2506 Degfigrastim (Neulasta) does not require additional review at	(Herceptin) does
Chical Scenario Ceview & Continue Your request for J9045 [Carboplatin (Paraplatin), J9171] Docetaxel (DOCEtaxel), J9306] Pertuzumab (Perjeta), J9355] Trastuzumab (Herceptin) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for J2506] Pegfilgrastim (Neulasta) does not require additional review at this time Your request for the formation for WBC Growth Factor Water for the methy or reducing Your addition theory or reducin	
eview & Continue four request for J9045 Carboplatin (Paraplatin), J9171 Docetaxel (DOCEtaxel), J9306 Pertuzumab (Perjeta), J9355 Trastuzumab (Herceptin) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) does not require additional review at this time four request for J2506 Pegfilgrastim (Neulasta) four request for State state to the State State to t	/ 14
Height 60 Inches Weight 130 pounds Traps Dese Amount Route Desay Excluded Cycling Carlogistin 000 0ALK 000 0ALK 000 0ALK 000 0ALK 010 000 Mg Oversame (Contraction) 000 0ALK 000 0ALK 010 000 Mg 01 01 Oversame (Contraction) 000 0ALK 000 0ALK 010 000 Mg 01 01 Oversame (Contraction) 000 0ALK 010 000 Mg 01 01 01 Oversame (Contraction) 000 0ALK 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 01 01 01 01 Oversame (Contraction) 000 0Mg 01 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 01 01 Oversame (Contraction) 000 0Mg 000 0Mg 01 0	
Drugs Does Amount Final Does Route Daily Frequency Schedule Cycle Length 00000400 (00000400 (00000400 (00000400) (0000400) (000040000000000	
Carbinglatin (Paraplatin) December 2000 Mick and Paraplatin) December 2000 Mick and 2000 Mick and 20000 Mick and 2000 Mick an	Cycles
Additional Clinical Information Has the disease tria preparise onter prior onter prio	Qides 1-4
Has the disease 140 progressed on or affect prior treatment that containing preprints? Additional Clinical Information for WBC Growth Factor Rules Applied Member Age is not Greater Than or Equal To 85 Years. ECCO is not 3 - 4 Which one of the Stational grid. Factors failurating rid. Factors	10
Additional Clinical Information for WBC Growth Factor Rules Agelied Member Age is not Greater Than or Equal To 63 Years, ECOO is not 3 - 4 Which ene of the Prior chemotherapy or radiation therapy failowing risk factors does the individual	
Rules Applied Member Age is not Greater than or Equal To 65 Years. ECOG is not 3 – 4 Which one of the Prior chemotherapy or radiation therapy following risk factors: does the individual	/ 66
inver .	
	Dut contract

Messaging regarding the requested drugs will display at the top of the Review & Continue page

User will review a summary of each of the components of the request and can edit each section if needed via the "Edit" button on the right



Review and Continue

Biomarkers	🖋 Edit
Biomarkers HER2 Unknown	
Performance Status	/ Edit
Performance Status 0 ECOG	

Dosing Schedule

Height 60	Weight 130 pounds						
Drugs	Dose Amount	Final Dose	Route	Daily Frequency	Schedule	Cycle Length	Cycles
Carboplatin (Paraplatin) Docetaxel (DOCEtaxel) Trastuzumab (Herceptin) Trastuzumab (Herceptin) Pertuzumab (Perjeta) Pertuzumab (Perjeta)	6.000 AUC 75.000 MG/M2 8.000 MG/KG 6.000 MG/KG 420.000 MG 840.000 MG	900.000 MG 118.500 MG 472.000 MG 354.000 MG 420.000 MG 840.000 MG	IV	QD	D1 D1 D1 D1 D1 D1 D1	21 Days	Cycles 1-6

Additional Clinical Information

Has the disease	No
progressed on or	
after prior	
treatment that	
contained	
pertuzumab	

not require additio	045 Carboplatin (Par nal review at this time	aplatin), j9171 Doce	taxel (DOCEta	xal), j0306 Pa	irtuzumab (Perjeta), 1935	5 Trastucuma	ab (Herceptin) d	ices
Your request for J2	506 Pegfilgrastim (N	eulasta) does not requ	/ire additional	review at this	time			
Request Ser	vices							10
docetaxel, carbo	oplatin, trastuzumab	and pertuzumab (T	(9K)					
J9045 Carbople	rtin (Paraplatin) N							
19171 Docetax 19306 Pertuzur	nab (Perjeta) IV							
19355 Trastuzu	mab (Herceptin) N							
Supportive Drug								
J2506 Pegfilgra	stim (Neulasta) SC							
Clinical Scen	ario							16
Tumor	Type Breast							
Tumor Sub	Type invasive							
Path	Rage Stage I							
Line of Treat	ment 2nd line							
Biom kers								11
	183.114							
\leq	ER2 Unknown	, ,						
Perfo, hance	e Status							10
Dosing Sche	dule							100
Dosing Sche	dule ege 60 inches				Weight 130 pounds			/10
Dosing Sche H	dule eight 60 inches Dose Amou	nt Final Dose	Route	Daily Frequency	Weight 130 pounds Schedule	Cycle Length	Cycles	/10
Dosing Sche H Drugs Carbopizin	dule eight 60 inches Dose Amou	nt Final Dose	Route	Daily Frequency	Weight 130 pounds Schedule	Cycle Length	Cycles	/16
Dosing Sche H Drugs Carbopiatin Docetaxel (DC	dule eight 60 inches Dese Amou Clitane) 6,000 AUC 75,000 AUC	nt Final Dose	Route	Daily Frequency	Weight 130 pounds Schedule	Cycle Length	Cycles	200
Dosing Sche H Drugs Carbopiatin (Garapiatin) Docetavel (OC Trastucuma) Generoptin)	dule eight 60 inches Dese Amou 75.000 MGC 26.000 AUC 75.000 MGC 6.000 XGM	nt Final Dose 900.000 MS 118.500 MG 472.200 MS 5 354.000 MS	Route	Daily Frequency	Weight 130 pounds Schedule	Cycle Length 21 Days	Cycles	216
Dosing Sche H Drugs Carbopton (Skapjatin Oceased (DC Tractuumb Georegitii) Tractuumb	dule eight 60 inches Dese Ameu 50 000 AUC 75.000 MG/m 5000 MG/m 20000 MG/m 5000 MG/m 6000 MG/m 5000 MG/m	nt Final Dose 900.000 NG 412 118.500 NG 5 354.000 NG 5 354.000 NG 849.000 NG	Route	Daily Frequency	Weight 130 pounds Schedule	Cycle Length 21 Days	Cycles Cycles 1-6	710
Dosing Schee H Drugs Carbopatin (Skrappatin) Doortswel (Of Trottuurumb) Of Perturumb (Perturumb (Dese Amou 0.000 AUC 75.000 MG/I 2000 AUC 75.000 MG/I 420.000 MG/I 140.000 MG/I 140.000 MG/I 140.000 MG/I 140.000 MG/I 140.000 MG/I 140.000 MG/I	Final Dose 900.000 MS 118.300 MG 522.000 MG 324.000 MG 420.000 MG 420.000 MG	Route	Daily Frequency QD	Weight 130 pounds Schedule 01 01 01 01 01 01	Cycle Length 21 Days	Cycles Cycles 1-0	
Dosing Schee H Drugs Carboptatin Oncessor Discourse Discourse Pertuzumato Pertuzumato (clule Dese Amou Dese Amou 0.000 AUC CEExemb 0.000 AUC 25.000 MG/m 0.000 AUC 420.000 MG/m 420.000 MG heights 844000 MG	Final Dose 900.000 MS 118.500 MS 324.000 MS 324.000 MS 420.000 MS 420.000 MS	N	Daily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01 01	Cycle Length	Cycles Cycles 1-6	/
Dosing Sche H Drugs Cabopistin Decreare IO Decreare IO Decreare IO Decreare IO Decreare IO Decreare IO Decreare IO Pertucumes (Pertucumes (dule eight 60 inches Dese Ameu CEIsmet) 6.000 AUC 75.000 MG 0.000 AUC 20.000 MG 420.000 MG 420.000 MG 420.000 MG	nt Final Dose 900.000 MG 118.500 MG 324.200 MG 324.000 MG 324.000 MG 324.000 MG 340.000 MG ation	Route	Daily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles	/10
Dosing Sche H Drugs Carboptatin Orectamotion Decension D	dule Dese Amou Dese Amou 0.000 AUC CEENINE 0.000 AUC 20.000 AUC 20.000 AUC 20.000 AUC 40.000 AUC 10.000 AUC<	nt Final Dose 900.000 MS 118.500 MS 324.200 MS 324.000 MS 840.000 MS ation	Route	Daily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01	Cycle Length 21 Days	Cycles Cycles 1-6	100
Dosing Sche H Drugs Carbopizin @acapiatin Doctase(DC Traducume) Carbopizin Perturument Perturument Additional C Has the dil progressed	dule base Amou base Amou Base Amou CBISHIP 6.000 AUC 75.000 MG/m 20.000 MG/m 40.000 MG/m 40.000 MG/m Verystal 840.000 MG/m Inincal Inform merer mine a ND	nt Final Dose 900.000 MS 118.500 MS G 472.000 MS 420.000 MS 64.000 MS 840.000 MS	Route	Daily Frequency QO	Weight 130 pounds Schedule 01 01 01 01 01	Cycle Langth 21 Deys	Cycles Cycles 1-6	70
Dosing Sche H Drugs Carbopiztin Garbopiztin Doctasel GC TratoLizumo Decerceptin TratoLizumo MerityLinnel PerityLinnel Additional C	dule best Amou best Amou best Amou CEILINY 5.000 AUC S.000 AUC 5.000 AUC S.000 MG 420.000 MG Verystal 840.000 MG Ininical Inform energian Ininical Inform energian	nt Final Dose 900 000 MS 118, 500 MS 5 324,000 MS 420,000 MS 420,000 MS add.000 MS	Route	Oaily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01	Cycle Langth 21 Deys	Cycles 1-6	/10
Dosing Sche H Drugs Carboptatin (Varapitatin) Doctase(CC TratoLucmade) Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin) TratoLucmade Orecreptin)	dule sight 60 inches Dese Amou CREMEN 0 000 AUC SLOOD MCM CREMEN 0 000 AUC SLOOD MCM ADDOD MCM ADDOM MCM ADDOM MCM ADDOM ADD	nt Final Dose 900 000 MS 118, 500 MS 324,000 MS 420,000 MS 420,000 MS ation	Route	Daily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles Cycles 1-6	70
Dosing Sche H Drugs Carboptan Occase(OC TratoLucad) Doctase(OC TratoLucad) Occase(IC) TratoLucad) Mercutane(I	dule sight 60 inches Dese Amou CREMENT Dese Amou CREMENT Dese Amou CREMENT Dese Amou Accord a	nt Final Dose 900 000 MS 118, 500 MS 324,000 MS 420,000 MS 420,000 MS ation	Route	Daily Frequency	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles Cycles 1-6	700
Dosing Sche H Drugs Carbopatin Garbopatin Doctasel OC Tractuoundo Mercopitol Mercupitol	dule sight 60 inches Dese Amou Cetterer Soot Auc Cetterer Soot Auc Cetterer Soot Auc Accord auc Cetterer Soot Auc Accord auc	nt Final Doee 900 000 MS 118,500 MS 324200 MS 420,000 MS 420,000 MS ation for WB	Route N C Growt	only Frequency op	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01 01 01 01 01	Cycle Length 21 Deys	Cycles 1-6	100
Dosing Schee H Drugs Carbojatin Grapatin Ocortave (CO Doctave (CO Doctave) Generoptin Perfuzumatio Perfuzumatio Perfuzumatio Perfuzumatio Additional C Rules Ag	dule sight 60 inches Dose Amou Cetames 0 000 AUC Stood Mark 20000 MG 20000 MG 400000 MG 40000 MG 4000 MG 40000 MG 4000 MG 40000 MG 40000 MG 40000 MG 40000 MG 40000 MG 40000 MG 4000 MG 40000 MG 40000 MG 40000 MG 40000 MG 4000 M	nt Final Doce M2 900 000 MS S 372,200 MS S 372,000 MS S 370,000 MS ADD ON MS 394,000 MS ation ation for WB	V IV	000 00 h Factor	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 02 01 03 01 04 01 05 01 05 01 05 02 05 02 05 02 05 02 05 02 05 02	Cycle Length 21 Days	Cycles Cycles 1-6	700
Dosing Sche H Drugs Carbojatin Graduition Docetawei GO Docetawei GO Docetawei GO Docetawei GO Docetawei GO Docetawei GO Docetawei GO Perfuzumatio Pe	dule leght 60 inches Dese Amou CEtawel	Int Final Dose Int 500 000 MG Int 500 MG Int 600 MG Int	Route N	op op h Factor ars. 8000 is m	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles 1-0	700
Dosing Sche H Drugs Grabotan Grabotan Occased OD Docessed OD Doces	dule dule dule dule dule does Amou CELIMP dood AUC Theorem about the about the cellmical Inform about the price price price about the binical Inform about the binical Inform about the binical Inform bi	nt Final Doee 115,500 MG 115,500 MG 222,000 MG 222,000 MG 225,000 MG 255,000 MG 255	C Growtt	QD QD h Factor ars. ECOG is no	Weight 130 pounds schedule 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles 1-0	700
Dosing Sche H Drugs Carbojatin Oroctavel (Or Doctavel (Or Perturumation) Perturumation Perturum	dule eight 60 inches Dese Amou CEILANE (0000 AUC 75.000 MG 15.000 MG 1	Int Final Doce M2 900.000 MG 118.500 MG 254.000 MG 242.000 MG 354.000 MG 354.000 MG 364.000 MG ation for WB 364.000 MG ation for WB ation the	C Growt Igasi To 55 Ye	QD QD h Factor ars. ECOG is to	Weight 130 pounds Schedule 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01	Cycle Length 21 Days	Cycles 1-0	700

🖋 Edit

/ Edit

User will review a summary of each of the components of the request and can edit each section if needed via the "Edit" button on the right

When all the information is verified, submit the request by clicking the "Submit" button at the bottom of the page



Order request preview

3 corelon		Reprovider Porta
Order Request		Logo
o to Homepage Submit This Request		Save as PDF Print
hart documentation may be uploaded using the "Attack uthorized user.	n File" button below. You may come back later to View Order History	/ to edit any open drug(s). Select "Email" to share a link to this case with another <u>Email</u>
S3 corelon.		Provider Portal.
Order Request Previe	W	
Case Status:	Health Plan:	
Has Not Been Submitted		
Member Information:	Ordering Provider:	Dispensing Provider: 🖋 Edit
		Modify clinical

The Order Request Preview allows users to confirm the requested items prior to submission

The "Modify clinical" button can be used to make updates to previously entered information

Select the "Submit This Request" button to complete the order request



Order request preview

SS corelon.

@ ProviderPortal.

Case Status: Health Plan:	Status: it Been Submitted	Health Plan:	
Jambar Jafarmatian Diananaing Dravidary dan			
The more momentation: Ordering Provider: Dispensing Provider: Zeat	er Information:	Ordering Provider:	Dispensing Provider: ZEdit

The drug administration information is being displayed for the convenience of the user and has not been independently verified or clinically reviewed. Please note that one or more of these drugs may also require review by a pharmacy benefit manager prior to payment. Please contact the number listed on the back of the member's identification card for more information.

DRUG DETAILS:

ITEM # HC	PCS	DESCRIPTION		REQUEST STATUS
1 💿 J92	28	lpilimumab		
Dose range: Cycle length: Cycles/Duration: Direction:	204.12 mg 21 Days 1,2,3,4 cycles/ 84 Days 204.12 mg Day 1 QD Cycles 1,2,3,4		Treatments per Cycle: Total Treatments: Total Billing Units:	1 visits 4 820
2 💿 J92	99	Nivolumab		
Dose range: Cycle length: Cycles/Duration: Direction:	68.04 - 240 mg 21 Days 5,6,7,8,9,10 cycles/ 168 Days 240 mg Day 1 QD Cycles 5,6,7,8,9, 10; 68.04	l mg Day 1 QD Cycles 1,2,3,4	Treatments per Cycle: Total Treatments: Total Billing Units:	1 visits 10 1716

The Order Request Preview allows users to confirm the requested items prior to submission

Select the "Submit This Request" button to complete the order request



Attach Clinical Information, Optional

Diagnosis: C43.10 Mal melan unsp eyelid, incl canthus

Clinical Information: [-] Disease: Melanoma Pathology: Melanoma Stage: IV Treatment: Second Line Performance Status: 0 - Normal Activity (asymptomatic) Biomarkers: Microsatellite Instability - Not reported;c-kit status - Not reported;NTRK Fusion - Not reported;BRAF status - Unknown; Justification Questions: Does the individual have unresectable or metastatic disease?True Has the individual received prior treatment with another anti-PD-1 or anti-PD-L1 agent?False Is the individual receiving immunosuppressive drug therapy for an autoimmune disease or chronic condition?False

Drug Justification Questions:

ATTACHMENTS

(LIMIT: 20)





Should additional clinical need to be submitted, the **Attach File** option is located at the bottom of the Summary

Press "Attach File" and Browse for the record to attach

Additional clinical information screen

First Name Last Name USER Phone Ext (224) 279-5203 Email If you have entered "other", "unknown", or "none of these apply" to any of the clinical guestions, provide the additional clinical details supporting t request below. Also, provide any additional pertinent information to support a review of this procedure. Additional clinical information: (Maximum 1800 characters)	ease provide the Assessment and Plan information from the most recent Pro	aress Note or call us before the end	of the next husiness day at 8443771282
irst Name ast Name USER Phone Ext (224) 279-5203 Email Fyou have entered "other", "unknown", or "none of these apply" to any of the clinical questions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. Additional clinical information: (Maximum 1800 characters)			of the next business day at 0443771202
A Reco	irst Name		
ast Name USER Phone Ext (224) 279-5203 imail if you have entered "other", "unknown", or "none of these apply" to any of the clinical questions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest additional clinical information: (Maximum 1800 characters) Frequest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest below. Also, provide any additional pertinent information to support a review of this procedure. Idditional clinical information: (Maximum 1800 characters) Frequest below. Frequest below. Idditional clinical information: (Maximum 1800 characters) Frequest below. Idditional clinical information: (Maximum 1800 cha			REQUI
USER Ext (224) 279-5203 Ext (224) 279-520 Ext (224) Ext (224) Ext (224) Ext (224) Ext (224) Ext	ast Name		
hone Ext (224) 279-5203 imail imail ivou have entered "other," "unknown", or "none of these apply" to any of the clinical guestions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. idditional clinical information: (Maximum 1800 characters)	USER		REQUI
(224) 279-5203	hone		Ext
imail You have entered "other", "unknown", or "none of these apply" to any of the clinical questions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. dditional clinical information: (Maximum 1800 characters)	(224) 279-5203		
you have entered "other", "unknown", or "none of these apply" to any of the clinical questions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. dditional clinical information: (Maximum 1800 characters)	mail		
you have entered "other", "unknown", or "none of these apply" to any of the clinical guestions, provide the additional clinical details supporting t equest below. Also, provide any additional pertinent information to support a review of this procedure. dditional clinical information: (Maximum 1800 characters)			
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su dditional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su dditional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su dditional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su dditional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su dditional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
	you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
Perce O	f you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su additional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting th
Can	f you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su additional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting the REQUIN
	f you have entered "other", "unknown", or "none of these apply" to an equest below. Also, provide any additional pertinent information to su additional clinical information: (Maximum 1800 characters)	y of the clinical questions, provide pport a review of this procedure.	REQUIN the additional clinical details supporting the REQUIN

If a case does not auto approve, additional information may be included on the Additional clinical information screen

Note: Urgent cases submitted when the Call Center is closed must be indicated as such in the comments section; please also include a contact and phone number should a peerto-peer be required



 \mathbf{J}

Order request summary

Order Request	-	Logout
Withdraw this request Begin Another Request Go to Homepage		Save as PDF Print
Chart documentation may be uploaded using the "Attach File" button below. You may come back la user.	ar to View Order History to edit any open drug(s). Select "Email" to share a link to t	this case with another authorized
S3 carelon.		ReproviderPortal.
Order Request Summary	0: 135487923 te Pance: 04/29/2022 - 10/14/2022	Authorized
Health Plan: Start Date: 04/29/2022 Pathway Eligible ID: 135487923		
This order is not a guarantee of payment except when required by applicable law. When applical member's contract at the time of services provided.	le law allows, paymer If the ordering provider would like to discuss this case with a Carelon M	Logou Logo
Member Information: Ordering Provide	Begin Another Request Go to Homepage Chart documentation may be uploaded using the "Attach File" buttor authorized user.	Save as PDE Print
	S3 carelon.	© Provider Portal.
The days administration information is being displayed for th	Order Request Summary	Order ID: 135968163 In Progress Anticipated Determination Date: 02/24/2023
clinically reviewed. Please note that one or more of these dr payment. Please contact the number listed on the back of th	gs may also member's ic member's contract at the time of services provided.	by applicable law. When applicable law allows, payment is subject to the member's active enrollment, benefit limitation and other terms of the
Please call for all Urgent Requests.	Member Information:	Ordering Provider: Dispensing Provider: *Edit

Requests that meet clinical criteria will be approved upon case submission and will display as "**Authorized**"

Regimens that also satisfy Pathway criteria will receive a Pathway Eligible ID in addition to the Order ID

Requests that may require additional review will display as "**In Progress**"

Requests that included all non-managed drugs (AIM is not delegated to review), the banner will display "Completed" and all drug level details will state AIM Clinical Review not Required"



Order request summary - drug level details

The drug administration information is being displayed for the convenience of the user and has not been independently verified or clinically reviewed. Please note that one or more of these drugs may also require review by a pharmacy benefit manager prior to payment. Please contact the number listed on the back of the member's identification card for more information. Specialty drugs currently not requiring a prior authorization may change to requiring a prior authorization in the future.

Please call for all l

for all Urgent Requests.

DRUG DETAILS:

ITEM # HCI	PCS	DESCRIPTION		REQUEST STATUS
1 💿 J922	28	Ipilimumab		Authorized
Dose range:	204.12 mg		Treatments per	
Cycle length:	21 Days		Cycle:	1 visits
Cycles/Duration:	1,2,3,4 cycles/ 84 Days		Total Treatments:	4
Direction:	204.12 mg Day 1 QD Cycles 1,2,3,4		Total Billing Units:	820
2 💿 J929	99	Nivolumab		Authorized
Dose range:	68.04 - 240 mg		Treatments per	
Cycle length:	21 Days		Cycle:	1 visits
Cycles/Duration:	5,6,7,8,9,10 cycles/ 168 Days		Total Treatments:	10
Direction:	240 mg Day 1 QD Cycles 5,6,7,8,9, 10; 68.04	4 mg Day 1 QD Cycles 1,2,3,4	Total Billing Units:	1716

The Order Request Summary provides detailed drug-level review outcomes

Additional information regarding next steps is provided in the health plan specific disclaimer located above the requested items

Configurable Status Options:

Authorized Non-Authorized Refer to Health Plan Refer to PBM AIM Clinical Review Not Required







How to submit PCCA case for Radiation Therapy



40

Step 1 – Confirm PCCA Review Type Step 2 – User Selects Ordering Provider

rom the list below.						
	Recent	Favorites	Search Results			View: Local 🗸
Orderi	, pa Providers					
Favorit	Post Medical Nec	essity Review			rta Specialty	त्वे Health Plan त्वे
*	Has the Healt after the claim	th Plan directed you to / m was processed?	AIM to submit a Post Clair	m Case	Internal Medicine	Optima Health
*	Please provide	e the following informatio	on		Other	Optima Health
×	Claim Numbe	r	Claim Submission D	ate	Other	
	🗆 I do not h	ave this information			DISFLATIN	Withdraw this request
	ОК					

All other intake steps after this point are the same as a prospective case (Select Ordering Provider, Servicing Provider and complete Clinical Intake)

- System recognizes the user is initiating a PCCA case
- User validates the PCCA request and enters claim number
 - PCCA claim numbers consist of 11 digit alpha-numeric values.
 - If claim only has 10 digits add a '0' at the end
- User searches and selects Ordering Provider

Step 3 – Select Planning Start Date

Hide Details

85DUCK, DAISY	I Edit		
Member #:	3333333330	Treatment Start Date:	6/1/2020
Date of Birth:	1/1/1985	Health Plan:	
Ordering Provider:	DAGEFORDE, DA	VID 💉 Edit	

Step 3: Please enter the Planning Start Date if it prior to the Treatment Start Date

919 #11

Planning Start Date 06/01/2020

53

τz

Next Delete this request

Have a <u>comment or suggestion?</u> Copyright © 2000–2020 AIM Specialty Health. All Rights Reserved.

User selects Planning Start Date / Simulation Date

Step 4 – Select Servicing Provider

 BSDUCK, DAISY
 ✓ Edit
 Hide Details

 Member #:
 333333330
 Treatment Start Date:
 6/1/2020

 Date of Birth:
 1/1/1985
 Health Plan:
 T

 Ordering Provider:
 DAGEFORDE, DAVID // Edit
 Edit
 T

Step 4: Please Choose a Provider

TO

Provider Search	In Network Out of Ne	twork						
Facility Name:	Provider Search Results							
	Facility	🟚 Address 😰	City 🔯	State 🟚	Phone 🟚	Distance	Action	Мар
City:	BAPTIST HEALTH LEXINGTON	1740 NICHOLASVILLE RD	LEXINGTON	KY	(859) 260-6100 🕲	158.90	<u>View</u> Details	<u>View</u> Map
State				K/V	(050) 260 6100 @	150.00	Manu	Mour
Zin Code:	DAPTIST HEALTH LEXINGTON	1740 NICHOLASVILLE RD	LEXINGTON	KT.	(859) 200-0 100	156.90	Details	Map
	BAPTIST HEALTH LEXINGTON	2100 NICHOLASVILLE RD	LEXINGTON	KY	(859) 260-6197 ् ®	159.40	View Details	<u>View</u> <u>Map</u>
Group NPI:	BAPTIST HEALTH LEXINGTON	1775 ALYSHEBA WAY	LEXINGTON	KY		164.61	<u>View</u> Details	<u>View</u> Map
Search <u>Clear</u>	ENDOSCOPY AND SURGICAL CENTER OF LEXINGTON CLINIC	1225 S BROADWAY STE 200	LEXINGTON	KY	(859) 258-4100 (®	157.79	<u>View</u> Details	<u>View</u> Map
	GEORGETOWN COMMUNITY HOSPITAL	1140 LEXINGTON RD	GEORGETOWN	KY	(502) 868-1100 رھ	147.74	<u>View</u> Details	<u>View</u> <u>Map</u>
	KENTUCKY RENAL CARE LEXINGTON EAST	1101 WINCHESTER RD STE 100	LEXINGTON	KY	(859) 225-4922 🔊	159.04	<u>View</u> Details	<u>View</u> Map
	LEXINGTON CLINIC AMBULATORY SURGERY CTR	1225 S BROADWAY STE 100	LEXINGTON	KY	(859) 258-4000 🕲	157.79	<u>View</u> Details	<u>View</u> <u>Map</u>
	LEXINGTON DIAGNOSTIC CENTER	1725 HARRODSBURG RD STE 100	LEXINGTON	KY	(859) 278-7226 🕲	157.84	<u>View</u> Details	<u>View</u> Map
	LEXINGTON FOOT CENTER	1901 LEITCHFIELD RD	OWENSBORO	KY	(270) 684-5252	161.88	<u>View</u> Details	<u>View</u> <u>Map</u>
	IKK KK 1 2 3 4 10 10			C	DISPLAYING	1–10 OF	32 RES	BULTS
	Return to Provider List Submit a Facili	V					Delete	this request

- Select or search for a servicing provider
 - Facility Name
 - Group NPI

•OR

 Enter a provider manually by selecting "Submit a Facility"



Step 5 – Select Procedure

DUCK, DAISY	Show Details		
5: Please select the desired procedure.			
adiation Therapy Procedure			
Please begin by either the Primary Treatment and /	or Boost:		
Primary Treatment:	0		
Proton Beam (CPT 77520)	\checkmark		
Boost:	0		
Proton Beam (CPT 77520)	\checkmark		
elect all Associated Services being requested:			
Special radiation treatment (CPT 77470)			
Special radiation physics consult (CPT 7737	D)		
Image-guided radiation therapy (IGRT) (CPT	77387)		
Hydrogel Spacer (CPT 55874)			
(0,1,000,1)			
Continue Delete this request			

- Select Primary
 Treatment and Boost
- Select Associated Services



Step 6 – Enter Clinical Information

tep 5: Please enter the Patie	nt Disease Information.			
Patient Disease Details				
Treatment is for:	Primary Tumor	O Metastatic Lesion	◯ Other	
Diagnosis	Prostate Cancer			•
Pathology	Adenocarcinoma			•
TNM or Staging	⊖ TNM	 Stage 	O Unknown	
Stage	IIA			•
Bio-Markers				
Gleason Score	7			•
PSA	4.1 - 9.9 ng/ml			Ŧ
Treatment	Definitive			•
Goal	Curative			•
Performance Status	0 - Normal Activity	(asymptomatic)		•

Continue

83

Enter clinical information

- Please note: You have the option to enter TNM or Staging.
- When you finish, click "Continue".

Step 7 – Continue Entering Clinical Information

Hide Details

FC

231BEAR, YOGI

Member #: 0022310XU03 Treatment Sta Date of Birth: 1/1/1994 Health Plan: Ordering Provider: SMITH, JOHN H	rt Date: 11/1/2020 Optima Health
PROCEDURES REQUESTED (1)	ENTER MEMBER'S CLINICAL INFORMATION
Proton Beam Includes Boost >	Please answer the following questions to provide as much information as possible for clinical review. DIAGNOSIS Prostate Cancer CLINICAL INFORMATION *Is this request for repeat irradiation in a previously treated field? Yes No Vinknown *Has an IMRT or EBRT plan been done? Yes No Vinknown *Would dose tolerance of surrounding normal structures be exceeded with 3D conformal radiation or IMRT? Yes No
	O Unknown All clinical questions have been answered, select Next to continue.
	Delete this request Save and Exit Next

When finished, click "Next".

If you answer "unknown" or further review is required, you will see this screen

ADDITIONAL INFORMATION	
* FIRST NAME	~
DEMOREP	
*LAST NAME	
USER	
* PHONE NUMBER	
(800) 123-4567	
EXT	
*FAX NUMBER	
(800) 123-4567	
* Provide additional information that may be helpful in reviewing this request.	ł
N/A	~
Continue Cancel	



- Fill out the necessary information.
- You can type any additional clinical information in the box below or you will have the opportunity to upload clinical documents in the end.
- If you chose not to type any information, please type "N/A" in the box
- When finished, click "Continue".

Step 8 – Continue Entering Clinical Information

231BEAR, YOGI Member #: 0022310XU03 Treatment State Date of Birth: 1/1/1994 Health Plan: Ordering Provider: SMITH, JOHN H	Hide Details art Date: 11/1/2020 Optima Health	
PROCEDURES REQUESTED (1)	ENTER MEMBER'S CLINICAL INFORMATION	
Proton Beam Includes Boost ►	Please answer the following questions to provide as much information as possible for clinical review. If Total Planned Dosage is not available, please, enter 1. DIAGNOSIS Prostate Cancer TREATMENT INFORMATION Treatment Start Date 11/01/2020 Treatment End Date 01/29/2021	
	* Planned total dose (Gy) 28 Gy * Total number of fractions 10 fractions All treatment information has been entered, select Next to continue.	Maut
	Delete this request Save and EXIT	Next

S

Click "Next" to continue

Step 9 – Review entered information, continue with request once verified

REQUEST SUMMARY	Expand All 🔻
Proton Beam Includes Boost	
Prostate Cancer	
No additional information is required.	
Treatment Summary	<u></u> Ædit Treatment
► Clinical Details	🥖 Edit Clinical
Save and Exit	Continue Delete this request

Click "Continue"



Order request preview

Crder Request		Logou
Submit This Request Go to Homepage Delete this	request	Save as PDF Print
DEMO		© Provider Portal.
Order Request Preview		
Request Status: Has Not Been Submitted	Health Plan:	
Member Information: 85MORGENDORFFER, DARIA	Ordering Provider: SCULLY, THOMAS	Servicing Provider: <a>Edit NORTHEAST REGIONAL MEDICAL CENTER
Member #: YRN3766999880 PO BOX 464	2 PROGRESS POINT PKWY OFALLON, MO 63368	315 S OSTEOPATHY AVE KIRKSVILLE, MO 63501
CHICAGO, IL 60622	Phone: 314-645-6454	Phone: 660-785-1000
Date of Birth: 1/1/1961	Fax: 314-434-1814	Fax: 660-785-1027
Phone: 312-999-9928	INF1: 1202082000	NMI: 1104899442

The Clinical Information displayed was obtained by AIM through the order entry process. The information is being displayed for the convenience of the user and has not been independently verified or clinically reviewed.

This is a preview of your order.

Select **"Submit This Request**" to proceed.

Orde	er Requ Plan:	uest Sumi	mary	Order ID: Valid Date Ran	ge: 02/18/2022 - 0 9	5/30/2022	Authorize
Optima H This order is enrollment,	Health s not a guarante benefit limitatio	03/02/2022 ee of payment except w n and other terms of the	vhen required l e member's co	y applicable law. When ntract at the time of se	n applicable law allows, p	ayment is subject to the	member's acl
Membe	r Informati	ion:	Orderin	g Provider:	Sen	vicing Provider:	
						I	
The Cli informa verified	nical Infor ation is bei I or clinica	mation display ing displayed fi Ily reviewed.	ed was c or the co	btained by All	/I through the or ne user and has	I der entry proce not been indep	ess. The bendently
The Cli informa verified Please	nical Infor ation is bei I or clinica call 844-3	mation display ing displayed fi Ily reviewed. 377-1282 for al	red was o for the co Il Urgent	btained by All nvenience of th Requests.	// through the or ne user and has	I der entry proce not been indep	ess. The bendently
The Cli informa verified Please REQU	nical Infor ation is bei I or clinica call 844-3 ESTED F	mation display ing displayed fi Ily reviewed. 377-1282 for al PROCEDURE	red was o for the co Il Urgent E(S)	btained by All nvenience of th Requests.	// through the or ne user and has	I der entry proce not been indep	ess. The bendently
The Cli informa verified Please REQU	nical Infor ation is bei l or clinica call 844-3 ESTED F	mation display ing displayed fi Ily reviewed. 377-1282 for al PROCEDURE	red was o for the co Il Urgent E(S)	btained by All nvenience of th Requests.	A through the or ne user and has REQUEST STATUS	I oder entry proce not been indep	ess. The bendently
The Cli informa verified Please REQU	nical Infor ation is bei I or clinica call 844-3 ESTED F PROCEDU Stereotact	mation display ing displayed fi Ily reviewed. 377-1282 for al PROCEDURE RE ic - Body or Spinal Co	red was o for the co II Urgent E(S)	btained by All nvenience of th Requests. DISEASE Brain Metastasis	A through the or ne user and has REQUEST STATUS Authorized	I order entry proce o not been indep REASON Criteria Met	ess. The pendently Act Hide D

ЭП

The order has now been submitted.

Requests that meet clinical criteria will be adjudicated real time upon case submission.

Approved orders will have a status of "**Authorized**" along with an "**Order ID**".

Review the Request status and authorized CPT codes for the approved service

92

83

REQUE	STED F	PROCEDURE(S)				
ITEM #	PROCEDURE		DISEASE	REQUEST STATUS	REASON	ACTION
1	Stereotact	ic - Body or Spinal Cord	Brain Metastasis	Authorized	Criteria Met	Hide Details
Planned Tor CPT Code 77373 63620 77295 77301 77338 77435	tal Dose: 27 Quantity Up to 3 Up to 5 Up to 2 Up to 2 Up to 3 Up to 5	Gy Included CPT Codes 77373, G0339, G0340 61796, 61797, 61798, 61799, 6 77295 77301 77338 32701, 77435	3620, 63621			
2	Special tre	atment procedure	Brain Metastasis	Authorized	Criteria Met	Hide Details
CPT Code 77470	Quantity Up to 1	Included CPT Codes 77470				
3	Special ph	ysics consult	Brain Metastasis	Authorized	Criteria Met	Hide Details
CPT Code	Quantity	Included CPT Codes				

The Order Summary outlines the CPT codes authorized as well as the maximum quantities

You can "Print" or "Save to a PDF" to include in the patient's chart.

Questions?



Please contact your Health Plan Network Representative

